Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Jerzy E, Tyczynski"'
Autor:
Alexander Liede, Wendy Sebby, Ashok Kumar Reddy Miriyala, Ravi Potluri, Debasish Mazumder, Anirban Ghosh, Eros Papademetriou, Ryan Kilpatrick, Jerzy E. Tyczynski
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-12 (2023)
Abstract Background Incidence and risk factors for seizures among women with advanced breast cancer (BC) and brain metastases are not well characterized across treatment-related or clinical subtypes. This study leveraged a large real-world dataset to
Externí odkaz:
https://doaj.org/article/19871ee041e848059b3c15908459e700
Autor:
Jerzy E. Tyczynski, Lia Gutierrez, Rishi Deka, Amy Sainski, Junjie Ma, Tapashi Dalvi, David D. Stenehjem, Casey R. Tak, Marisa B. Schauerhamer, Claire Telford, Joseph Biskupiak, James A. Kaye, Sudhir Unni, Diana I. Brixner, Hillevi Bauer, Xiangyang Ye
Publikováno v:
Breast Cancer Research and Treatment. 186:839-850
Germline BRCA mutations (BRCAm) strongly influence the risk of developing breast cancer. This study aimed to understand the role of BRCAm testing in affected individuals and to assess its impact on the outcome of BRCAm carriers compared to non-carrie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::24d9cd4568eaf6f4d1dfff6318c4c3b1
https://doi.org/10.1007/s10549-020-06038-x
https://doi.org/10.1007/s10549-020-06038-x
Autor:
Fabio A, Lievano, Linda J, Scarazzini, Jerzy E, Tyczynski, Charles M, Schubert, Cheryl L, Renz
Publikováno v:
Drug safety. 44(7)
Antibody-drug conjugates (ADCs) are new treatment options for certain cancers, especially those in advanced states with limited treatment options. Their unique design provides targeted therapy with toxins that otherwise would not be available, but th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::58656558c1c8a01ec078d70c1ff291dd
https://pubmed.ncbi.nlm.nih.gov/33988833
https://pubmed.ncbi.nlm.nih.gov/33988833
Autor:
David D, Stenehjem, Claire, Telford, Sudhir K, Unni, Hillevi, Bauer, Amy, Sainski, Rishi, Deka, Marisa B, Schauerhamer, Xiangyang, Ye, Casey R, Tak, Junjie, Ma, Tapashi B, Dalvi, Lia, Gutierrez, James A, Kaye, Jerzy E, Tyczynski, Diana I, Brixner, Joseph E, Biskupiak
Publikováno v:
Breast cancer research and treatment. 186(3)
Germline BRCA mutations (BRCAm) strongly influence the risk of developing breast cancer. This study aimed to understand the role of BRCAm testing in affected individuals and to assess its impact on the outcome of BRCAm carriers compared to non-carrie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8f45000659d91957201e3f7c35934b58
https://pubmed.ncbi.nlm.nih.gov/33389410
https://pubmed.ncbi.nlm.nih.gov/33389410
Publikováno v:
Blood. 136:44-45
Introduction: While survival for patients with newly diagnosed CLL has improved over the past decade, investigations suggest that benefits have largely accrued among younger adults, with much more modest benefits observed in older adults. The objecti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b2fec568d899e10dfe195b71149bf7d1
https://doi.org/10.1182/blood-2020-139897
https://doi.org/10.1182/blood-2020-139897
Autor:
Chantal Avila, Jerzy E. Tyczynski, Lia Gutierrez, Jiaxiao M. Shi, Reina Haque, Tapashi Dalvi, Monica Alvarado, James A. Kaye, Claire Telford, George E. Tiller
Publikováno v:
The Permanente Journal. 22
Context Little information exists on whether breast cancer survival differs by BRCA1 or BRCA2 mutation.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b830f4e88c6d763daa55503127f7c9d
https://doi.org/10.7812/tpp/17-197
https://doi.org/10.7812/tpp/17-197
Autor:
Janet L. Espirito, Jerzy E. Tyczynski, Ancilla W. Fernandes, Michael A. Bookman, Thomas Wilson
Publikováno v:
Gynecologic oncology. 146(1)
To understand the relationship between primary platinum-free interval (PFI), BRCA mutation status, and overall survival (OS) in patients with recurrent ovarian cancer receiving multiple lines of therapy in a multicenter, community-based, retrospectiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9024e8438374fa7794d23c8649fc565
https://pubmed.ncbi.nlm.nih.gov/28454659
https://pubmed.ncbi.nlm.nih.gov/28454659
Autor:
Jerzy E. Tyczynski, Mads Thomassen, Inge Søkilde Pedersen, Lia Gutierrez, Anders Kjærsgaard, Deirdre Cronin-Fenton, James A. Kaye, Claire Telford, Mette Nørgaard, Henrik Toft Sørensen, Jan Lewis
Publikováno v:
Cronin-Fenton, D P, Kjærsgaard, A, Nørgaard, M, Pedersen, I S, Thomassen, M, Kaye, J A, Gutierrez, L, Telford, C, Lewis, J, Tyczynski, J E & Sørensen, H T 2017, ' Clinical outcomes of female breast cancer according to BRCA mutation status ', Cancer Epidemiology, vol. 49, pp. 128-137 . https://doi.org/10.1016/j.canep.2017.05.016
Cronin-Fenton, D P, Kjaersgaard, A, Norgaard, M, Pedersen, I S, Thomassen, M, Kaye, J A, Gutierrez, L, Telford, C, Lewis, J, Tyczynski, J E & Sorensen, H T 2017, ' Clinical outcomes of female breast cancer according to BRCA mutation status ', Cancer Epidemiology, vol. 49, pp. 128-137 . https://doi.org/10.1016/j.canep.2017.05.016
Cronin Fenton, D, Kjærsgaard, A, Nørgaard, M, Pedersen, I S, Thomassen, M, Kaye, J A, Gutierrez, L, Telford, C, Lewis, J, Tyczynski, J E & Sørensen, H T 2017, ' Clinical outcomes of female breast cancer according to BRCA mutation status ', Cancer epidemiology, vol. 49, pp. 128-137 . https://doi.org/10.1016/j.canep.2017.05.016
Cronin-Fenton, D P, Kjaersgaard, A, Norgaard, M, Pedersen, I S, Thomassen, M, Kaye, J A, Gutierrez, L, Telford, C, Lewis, J, Tyczynski, J E & Sorensen, H T 2017, ' Clinical outcomes of female breast cancer according to BRCA mutation status ', Cancer Epidemiology, vol. 49, pp. 128-137 . https://doi.org/10.1016/j.canep.2017.05.016
Cronin Fenton, D, Kjærsgaard, A, Nørgaard, M, Pedersen, I S, Thomassen, M, Kaye, J A, Gutierrez, L, Telford, C, Lewis, J, Tyczynski, J E & Sørensen, H T 2017, ' Clinical outcomes of female breast cancer according to BRCA mutation status ', Cancer epidemiology, vol. 49, pp. 128-137 . https://doi.org/10.1016/j.canep.2017.05.016
Background To investigate breast cancer prognosis (disease-free (DFS) and overall survival (OS)) among carriers of germline BRCA mutations (BRCAm) in Denmark. Methods We identified all women in Central and Northern Denmark diagnosed with breast cance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71834ce4d84e6ee6ddfa6e0259f7a9bb
https://vbn.aau.dk/da/publications/d07eb74f-349e-41b9-b962-d0858e905941
https://vbn.aau.dk/da/publications/d07eb74f-349e-41b9-b962-d0858e905941
Publikováno v:
Gynecologic oncology. 146(1)
Evaluate literature to assess response rate as a surrogate endpoint of survival in ovarian cancer (OC).Systematic review consistent with PRISMA criteria, identified randomized, controlled trials reporting overall survival (OS), progression-free survi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9fe312ec93a8f1228230e09a2ca38a85
https://pubmed.ncbi.nlm.nih.gov/28395896
https://pubmed.ncbi.nlm.nih.gov/28395896
Autor:
Karin Berger, C. de Moor, Birgit Ehlken, C. Schroeder, Jerzy E. Tyczynski, J. Driedger, L. Hofmann-Xu, G. Paulus, J. Clune
Publikováno v:
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 17(7)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::326d8ea159826ed2e253fd001da53254
https://pubmed.ncbi.nlm.nih.gov/27202417
https://pubmed.ncbi.nlm.nih.gov/27202417